

# Fourth Quarter and Full Year 2016 Earnings Call

March 23, 2017

#### **Disclaimer**

The market and industry information contained in this presentation has not been independently verified. No representation or warranty, whether express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. Neither Hanwha Q CELLS Co., Ltd. ("the Company") nor any of its affiliates, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation.


This presentation contains statements that reflect the Company's beliefs and expectations about the future. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends, "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's operations and business outlook, contain forward-looking statements. These forward-looking statements also include 1Q17, 1H17, 2H17 and full-year 2017 estimates for revenues, PV product shipments, production capacities and other results of operations. Forward-looking statements involve inherent risks and uncertainties and actual results may differ materially from such estimates depending on future events and other changes in business climate and market conditions. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

No part of this presentation may be reproduced, photocopied, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization/firm) or published, in whole or in part, for any purpose. No part of this presentation may be distributed, reproduced, taken or transmitted into the United States, Canada or Japan.





## **Key Highlights**

in \$mil (except for GM and Earnings per ADS)	4Q16	3Q16	4Q15
Net Revenues	565.9	707.8	702.1
Gross Margin (%)	9.5%	19.9%	19.1%
Operating Income	(6.1)	72.4	53.8
Net Income	(25.5)	41.7	26.0
Earnings per ADS (\$, fully diluted)	(0.31)	0.50	0.31




- Achieved record high full-year results with substantial y-o-y improvement despite weaker-than-anticipated quarterly results
- Continued improvement of financial strength through prudent capital management
  - Net Debt<sup>1</sup> to Equity ratio at 194% vs. 256% a year ago
  - Cash conversation cycle maintained at 54-day







#### **Quarterly Financial Performance Overview**



#### Manufacturing Capacity Overview (as of December 31, 2016)


#### **Manufacturing Capacity** (Annualized)


in MW	4Q15	4Q16	4Q17 (E)
Module	3,800	4,150	4,600
Cell	3,700	4,150	4,600
Wafer	900	950	1,100
Ingot	1,400	1,550	1,650

- Estimated cell and module capacity expansions by YE2017 are mainly from efficiency improvement.
- Additional access of module supply of up to 1,550 MW (annualized) as of December 31, 2016 from Hanwha Q CELLS Korea, an affiliated company



### Q.ANTUM Cell Technology Ramp-Up & Module Power Roadmap







# **Income Statement Summary** (unaudited)

in \$mm, except share data	4Q15	1Q16	2Q16	3Q16	4Q16	Q/Q	Y/Y
Net Sales	702.1	514.9	638.0	707.8	565.9	(141.9)	(136.2)
Gross Profit	134.2	109.0	151.2	140.5	54.0	(86.5)	(80.2)
Selling expenses	36.3	22.8	33.1	36.4	27.9	(8.5)	(8.4)
G&A expenses	30.2	17.9	19.6	19.7	20.3	0.6	(9.9)
R&D expenses	13.9	11.6	14.0	12.0	11.9	(0.1)	(2.0)
Operating income (loss)	53.8	56.7	84.5	72.4	(6.1)	(78.5)	(59.9)
Income Tax Benefit (Expenses)	(4.6)	(4.6)	8.8	(10.3)	5.4	15.7	10.0
Net Income (Loss)	26.0	27.5	76.8	41.7	(25.5)	(67.2)	(51.5)
Share count-ADS (Diluted)	83.2	83.2	83.2	83.2	83.2		
Earnings(Loss) per ADS (Diluted)	\$0.31	\$0.33	\$0.92	\$0.50	(\$0.31)	(\$0.81)	(\$0.62)
Capital expenditures	37.7	53.1	36.5	23.0	25.1	(2.1)	(12.6)
Cash, cash equivalents	200.0	327.3	255.4	254.8	390.9	136.1	190.9



# Balance Sheet Summary (unaudited)

in \$mm	December 31, 2016	September 30, 2016	Q/Q
Cash & Cash Equivalents, & Restricted Cash	499.0	402.0	97.0
Account and Notes Receivable (Inc. Related Party), net	415.1	453.1	(38.0)
Inventories	333.5	451.7	(118.2)
Fixed Assets, net	758.4	822.6	(64.2)
Total Assets	2,198.7	2,447.5	(248.8)
Accounts and Notes Payable (Inc. Related Party)	435.7	529.6	(93.9)
Deferred Revenue	18.9	24.9	(6.0)
Short-term Debt (Inc. current portion of long-term debt)	527.9	414.9	113.0
Long-term Debt	643.7	796.9	(153.2)
Total Liabilities	1,796.1	1,970.0	(173.9)
Total Equity	402.6	477.5	(74.9)



